《大行報告》摩通下調再鼎醫藥-SB(09688.HK)目標價至90元 評級「增持」
摩根大通發表研究報告指,基於再鼎醫藥(09688.HK)(ZLAB.US)首季業績表現,將今明兩年經調整每股虧損預測由6.87美元及3.88美元,調整爲虧損3.55美元及1.1美元。
該行表示,再鼎醫藥定位頗具吸引力,認爲公司產品管道風險較低,其他業務發展具潛力,預期中國的行業監管及改革具有長期的推動作用,根據估值變化及營運開支預測等,目標價由105.9元下調至90元,予「增持」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.